Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome — SLO RP

Usher Syndromes Clinical Trial

Official title:
Safety and Efficacy of NPI-001 Tablets Versus Placebo for Treatment of Retinitis Pigmentosa Associated With Usher Syndrome

Status Active, not recruiting

Clinical Trial Summary

This study will examine the safety and efficacy of NPI-001 Tablets as compared to placebo for 24 months in subjects with vision loss due to RP associated with Usher syndrome.

Clinical Trial Description

This study will examine the safety and efficacy of oral NPI-001 Tablets as compared to oral placebo tablets for 24 months in subjects with vision loss due to RP associated with Usher syndrome. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04355689
Study type	Interventional
Source	Nacuity Pharmaceuticals, Inc.
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	September 3, 2020
Completion date	May 2025

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03901391` - Prospective Open Clinical and Genetic Study of Patients With Retinitis Pigmentosa
	Recruiting	`NCT04665726` - Natural History Study of Usher Syndrome ( Light4Deaf )
	Recruiting	`NCT05355415` - Adaptive Optics Imaging of Outer Retinal Diseases
	Recruiting	`NCT03990727` - Phenotype Correlates Genotype of Inherited Retina Dystrophies, Retinitis Pigmentosa, Con>Rod Dystrophies.